ADORA2A and retinopathy of prematurity: Our identification of the hyperoxic phase as the effective window, together with selective and robust protection against pathological (but not physiological) angiogenesis, provide the preclinical evidence for translating A2AR antagonists as a novel therapeutic strategy for ROP treatment.